ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 4.64% | 1.89% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 4.64% | 1.89% | |||
| Cost of Revenue | -3.54% | -4.82% | |||
| Gross Profit | 11.32% | 8.84% | |||
| SG&A Expenses | -32.87% | 48.83% | |||
| Depreciation & Amortization | -0.51% | -0.65% | |||
| Other Operating Expenses | -79.60% | 107.70% | |||
| Total Operating Expenses | -20.43% | 42.46% | |||
| Operating Income | 21.07% | -43.91% | |||
| Income Before Tax | 18.25% | -41.81% | |||
| Income Tax Expenses | -0.81% | 1.59% | |||
| Earnings from Continuing Operations | 18.31% | -42.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 18.31% | -42.03% | |||
| EBIT | 21.07% | -43.91% | |||
| EBITDA | 24.88% | -56.95% | |||
| EPS Basic | 19.76% | -42.12% | |||
| Normalized Basic EPS | 19.61% | -41.36% | |||
| EPS Diluted | 22.27% | -38.01% | |||
| Normalized Diluted EPS | 19.61% | -41.36% | |||
| Average Basic Shares Outstanding | 1.89% | 0.00% | |||
| Average Diluted Shares Outstanding | 1.89% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
